Riskpilot← Back to searchSign inGet full accessXPHAGE BIOSOLUTIONS AS
ASActiveOrg 925174610Sem Sælands Vei 8, 7034 TrondheimResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20200 employees
Revenue 2025
NOK 0
EBITDA margin
—
+3% vs 2024
Equity ratio
98.4%
Financial strength
Net profit 2025
NOK -86K
+1% vs 2024
| Revenue | NOK 0 | — |
| EBITDA | NOK -61K | +3% |
| Net profit | NOK -86K | +1% |
| Total assets | NOK 152K | -36% |
| Equity | NOK 150K | -37% |
| Employees | 0 | — |
Legal name
XPHAGE BIOSOLUTIONS AS
Org number
925174610
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12. juni 2020
Share capital
NOK 150 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap. Daglig leder eller styrets leder hver for seg.
Company purpose
Forskning, utvikling, markedsføring og salg av medisinske, kjemiske og bioteknologiske produkter, samt dertil hørende virksomhet. Selskapet kan ha eierinteresser i foretak innen samme eller tilstøtende bransjer som naturlig faller sammen med dette.
Address
Sem Sælands Vei 8, 7034 Trondheim
Phone
+4746796346
Email
contact@xphage.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 1 257 | 186 | 0 | 0 |
| Staff expenses | −0 | −518 | −87 | −0 | −0 |
| EBITDA | −134 | 437 | 11 | −63 | −61 |
| Depreciation & amort. | −0 | −21 | −25 | −25 | −25 |
| EBIT | −134 | 416 | −14 | −89 | −87 |
| Net financials | 0 | 0 | −1 | 1 | 0 |
| Profit before tax | −134 | 416 | −14 | −87 | −86 |
| Tax | −0 | 52 | −1 | −0 | −0 |
| Net profit | −134 | 364 | −13 | −87 | −86 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 136 | 596 | 325 | 237 | 152 |
| Equity | 122 | 337 | 323 | 236 | 150 |
| Long-term debt | 0 | 1 | 0 | 0 | 0 |
| Short-term debt | 14 | 258 | 1 | 0 | 2 |
| Total debt | 14 | 259 | 1 | 0 | 2 |
EBITDA margin
-6141700.0%
This company
15.8%
Market median
-38871619% vs market
20212025
Equity ratio
98.4%
This company
38.2%
Market median
+158% vs market
20212025
Return on equity
-57.5%
This company
18.4%
Market median
-413% vs market
20212025
Net profit margin
-8623700.0%
This company
8.1%
Market median
-106465532% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
EA Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (1) | ||
TW Chief Executive Officer | Chief Executive Officer | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
| Board of Directors | 2021 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 33.33% | 33.33% | 2022 | |
| Individual | 16.67% | 16.67% | 2022 | |
| Individual | 16.67% | 16.67% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of XPHAGE BIOSOLUTIONS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Eivind Almaas | Chief Executive Officer | 0 companies |
| Tommy Walvåg | Chief Executive Officer | 0 companies |
| Celia Noel Walvåg | Board of Directors | 0 companies |